Clinics in Nevada
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What Nevada law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and verified listings.
Nevada at a glance
- Pharmacy regulator
- Nevada State Board of Pharmacy
- 503A framework
- Follows the federal 503A framework
- Telehealth prescribing
- Regulatory: Telehealth allowed
- Asynchronous prescribing
- Regulatory: Async allowed
- Compounded GLP-1 access
- Regulatory: Compounded GLP-1 limited
Verified clinics serving Nevada
No verified clinics serving Nevada are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.
Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.
Run a pharmacy, clinic, or telehealth service? Apply for a listing.
Peptide access rules in Nevada
Yes. A Nevada resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Nevada-licensed prescriber, including by telehealth, which Nevada defines (NRS 629.515) to include synchronous interaction, asynchronous store-and-forward systems, and audio-only interaction. A compounded peptide is available when it is eligible under federal 503A rules and dispensed by a pharmacy licensed by the Nevada State Board of Pharmacy, which licenses both in-state and out-of-state pharmacies that ship prescriptions to Nevada patients under NRS chapter 639. [1] [2] [4] [5] [6] [8]
Compounded GLP-1 access in Nevada
Nevada's broad telehealth definition makes app-based GLP-1 programs lawful on the prescribing side if the prescriber holds a Nevada license, and the dispensing pharmacy must be licensed by the Nevada State Board of Pharmacy. [1] [2] [9]
Research use only sellers in Nevada
Nevada's food and drug law (NRS chapter 585) prohibits selling adulterated or misbranded drugs, and NRS chapter 639 restricts dispensing of prescription drugs to licensed pharmacies and practitioners. [3] [7] [10]
Nevada notes on specific peptides
- Semaglutide: Available branded by prescription, including from a Nevada-licensed telehealth prescriber using synchronous or asynchronous telehealth under NRS 629.515. Compounded semaglutide is limited to the federal patient specific exception since April 22, 2025. [2] [9]
How to check a clinic in Nevada
- Confirm the prescribing clinician's license with the Nevada medical or nursing board.
- Ask which pharmacy compounds or dispenses the peptide and check it in the Nevada State Board of Pharmacy license lookup. [1] [4] [5] [6] [8]
- Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
- Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Nevada. [3] [7] [10]
Common questions in Nevada
Can I get a GLP-1 prescription in Nevada through an asynchronous telehealth app?
Nevada's definition of telehealth includes asynchronous store-and-forward and audio-only interaction, and a provider-patient relationship can be established through telehealth, so app-based care is allowed if the prescriber holds a Nevada license and meets the standard of care. [2]
Does a telehealth prescriber need a Nevada license?
Yes. NRS 629.515 requires a valid Nevada license or certificate to provide telehealth services to a patient located in Nevada, subject to narrow exceptions. [2]
Sources
- [1]Nevada State Board of Pharmacy
- [2]NRS 629.515, Telehealth: license required; establishment of relationship with patient
- [3]NRS chapter 639, Pharmacy
- [4]NRS 639.2328, Pharmacy located outside Nevada that dispenses prescriptions to patients located in Nevada: licensing
- [5]NAC 639.67053, Compounding standards (sterile compounded drug products, USP chapter 797)
- [6]NAC chapter 639, Pharmacy
- [7]NRS chapter 585, Food, drugs and cosmetics
- [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
- [9]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
- [10]21 U.S.C. 331, Prohibited acts